| Serena, Thomas |
NCT04457752: Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) |
|
|
| Recruiting | 4 | 124 | US | Dual Layer Amniotic Membrane (DLAM). Artacent® | SerenaGroup, Inc., Tides Medical | Chronic Diabetic Foot Ulcers | 03/22 | 03/23 | | |
| Recruiting | 4 | 292 | US | Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC | Cellution Biologics, SerenaGroup, Inc., LifeCell | Diabetic Foot Ulcer, Venous Leg Ulcer | 12/26 | 07/27 | | |
NCT03154619: Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers |
|
|
| Active, not recruiting | 2 | 80 | US | 0.1% TR 987, Beta glucan, Placebo gel | SerenaGroup, Inc., TR Therapeutics | Venous Leg Ulcer | 04/19 | 04/21 | | |
| Not yet recruiting | 1 | 40 | NA | NOX1416 plus SOC, ADVANOX, Placebo plus SOC | NOxy Health Products, LLC, SerenaGroup, Inc. | Diabetic Foot Ulcer | 11/25 | 01/26 | | |
NCT05687656: Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers |
|
|
| Completed | N/A | 30 | US | InnovaMatrix AC porcine placental ECM therapy | ConvaTec Inc. | Diabetic Foot Ulcer | 01/24 | 01/24 | | |
NCT05291169: Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers |
|
|
| Completed | N/A | 54 | US | Omeza® OCM™, Omeza® Complete Matrix, Multimodal Wound Matrix | Omeza, LLC | Venous Leg Ulcer | 11/23 | 03/24 | | |
NCT05608317: A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing |
|
|
| Recruiting | N/A | 20 | US | ALLEVYN Non-Adhesive | Molnlycke Health Care AB | Wounds, Wound of Skin, Wound Leg, Venous Leg Ulcer | 07/24 | 11/24 | | |
NCT05588583: A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. |
|
|
| Recruiting | N/A | 68 | US | Mepilex Up | Molnlycke Health Care AB | Wounds, Wound of Skin, Wound Leg, Wound; Foot, Diabetic Foot Ulcer, Venous Leg Ulcer | 03/24 | 03/24 | | |
CAMPSTIM, NCT06449638: Modified Platform Trial Assessing Multiple CAMPs and SOC Vs SOC Alone in the Treatment of Hard-to-Heal DFUs |
|
|
| Recruiting | N/A | 272 | US | Standard of Care, Revita, Relese, Cogenex, Enverse | StimLabs, SerenaGroup, Inc. | Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer | 06/26 | 08/26 | | |
CAMPAIGN, NCT06600724: Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs |
|
|
| Recruiting | N/A | 170 | US | Standard of Care, EPIEFFECT, EPIXPRESS | MiMedx Group, Inc., SerenaGroup, Inc. | Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer | 08/26 | 08/26 | | |
| Completed | N/A | 136 | US | Standard Wound Care Alone, Stand Wound Care plus IPC | Huntleigh Healthcare Ltd, SerenaGroup, Inc. | Venous Leg Ulcer | 03/24 | 03/24 | | |
NCT06606210: INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone |
|
|
| Recruiting | N/A | 120 | US | InnovaMatrix® AC, Porcine Derived Extracellular Matrix | ConvaTec Inc. | Wound Heal, Venous Leg Ulcer | 07/25 | 04/26 | | |
NCT06437028: Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers. |
|
|
| Not yet recruiting | N/A | 170 | NA | Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care | Samaritan Biologics, Serena Group | Diabetic Foot Ulcer | 06/26 | 09/26 | | |
NCT06782386: Remote Temperature and Visual Monitoring to Help Manage Diabetic Foot Ulcers |
|
|
| Not yet recruiting | N/A | 100 | NA | OneStep Foot Scanner | Bluedrop Medical Limited, Serena Group | Diabetic Foot Ulcer (DFU) | 08/26 | 08/26 | | |
| Dhillon, Yadwinder |
NCT04457752: Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) |
|
|
| Recruiting | 4 | 124 | US | Dual Layer Amniotic Membrane (DLAM). Artacent® | SerenaGroup, Inc., Tides Medical | Chronic Diabetic Foot Ulcers | 03/22 | 03/23 | | |
BLADE-VG2, NCT05539963: A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis |
|
|
| Recruiting | 2 | 60 | US | STIMULAN VG, Systemic Antibiotics | Biocomposites Ltd, MCRA | Diabetic Foot Osteomyelitis | 12/24 | 12/25 | | |
| Recruiting | 2 | 230 | Europe, Canada, US | DBV1605 | DBV Technologies | Cow's Milk Allergy | 03/24 | 03/24 | | |
Mavericks, NCT05758545: Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers |
|
|
| Recruiting | N/A | 450 | US | COMS One device, Concurrent Optical and Magnetic Stimulation, Sham device | Piomic Medical, NAMSA | Diabetic Foot Ulcer | 06/27 | 06/27 | | |
| Walker, Kwadjo |
NCT04457752: Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®) |
|
|
| Recruiting | 4 | 124 | US | Dual Layer Amniotic Membrane (DLAM). Artacent® | SerenaGroup, Inc., Tides Medical | Chronic Diabetic Foot Ulcers | 03/22 | 03/23 | | |
